Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Immuron reports record FY26 revenue, outlines North America expansion plan

Aug 28, 2026, 6:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive earnings surprise with record revenue and cash, plus FDA IND and DoD collaboration create optionality for partnerships and NA market expansion; historically, similar milestones supported multi-quarter upside in small-cap biopharma stocks.

AI summary

What happened, with direct paths to the underlying reporting

Immuron posted FY26 revenue of A$7.7m, surpassing expectations with 6% growth and record cash of A$9.0m. US/Canada expansions, IND approvals, and strategic asset partnering underpin a North America-led growth plan for FY27, while Q3-Q4 milestones aim to widen Travelan uptake and partnerships.

FY26 revenue hits a record A$7.7 million; net profit up.
Australia grew 10%; US sales +7% AUD, +13% USD.
Cash balance at A$9.0 million; no term deposits.
IMM-529 IND approved Nov 2025; IMM-124E topline results Dec 2025.
FY27 focuses on North America growth; multiple milestones ahead.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.